AZD-7594

Chemical Name:

3-(5-((1R,2S)-2-(2,2-difluoropropanamido)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)propoxy)-1H-indazol-1-yl)-N-(tetrahydrofuran-3-yl)benzamide

SMILES Code: 

O=C(NC1COCC1)C2=CC=CC(N3N=CC4=C3C=CC(O[C@H](C5=CC=C(OCCO6)C6=C5)[C@@H](NC(C(F)(F)C)=O)C)=C4)=C2

InChi Code:

InChI=1S/C32H32F2N4O6/c1-19(36-31(40)32(2,33)34)29(20-6-9-27-28(16-20)43-13-12-42-27)44-25-7-8-26-22(15-25)17-35-38(26)24-5-3-4-21(14-24)30(39)37-23-10-11-41-18-23/h3-9,14-17,19,23,29H,10-13,18H2,1-2H3,(H,36,40)(H,37,39)/t19-,23?,29-/m0/s1

InChi Key:

ZZWJKLGCDHYVMB-QMQODZDESA-N

Keyword:

AZD-7594, AZD 7594, AZD7594, AZ13189620, AZ-13189620, AZ 13189620, 1196509-60-0

Solubility: Soluble in DMSO

Storage: 0 - 4°C for short term (days to weeks), or -20°C for long term (months).

Description: 

AZD-7594, also known as AZ13189620, is an inhaled selective glucocorticoid receptor (GCCR) modulator. AZD-7594 is in phase II clinical trials by AstraZeneca for the treatment of mild to moderate asthma. It is also in phase I clinical trials for the treatment of chronic obstructive pulmonary disorder (COPD).

Target: GCCR